Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > CR at 450
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(74)
•••
Comment by consultant99on Jul 25, 2022 12:38pm
244 Views
Post# 34848473

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CR at 450

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CR at 450There is a lot of potential - I 100% totally agree with you. It might not be enough to just be able to make a vaccine that works but how this novel approach compares to existing vaccines.

Will it be quicker to make?
Will it be cheaper to make store and transport?
Will it have greater efficacy?
Will it be safer?
How adaptable to other viruses?

NVAX share price went from less than $5/share to over $300 briefly during the Covid vaccine gold rush. It is not hard to imagine TLT getting a big share price boost if the current animal testing is favourable and leads to human testing of a Covid vaccine.

The next 6-9 months could be liftoff with BTD AA for bladder cancer and moving towards human testing of a Covid vaccine. Will Roger be driving the bus by then?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities